DOP54 Efficacy and safety of ustekinumab through Week 16 in...

Journal of Crohn's and Colitis 2019 / 01 Vol. 13; Iss. Supplement

DOP54 Efficacy and safety of ustekinumab through Week 16 in patients with moderate-to-severe ulcerative colitis randomised to ustekinumab: results from the UNIFI induction trial

Danese, S, Sands, B E, O'Brien, C D, Zhang, H, Johanns, J, Sloan, S, Izanec, J, Szapary, P, Marano, C, Leong, R W, Rowbotham, D, Targan, S R, Van Assche, G
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
13
Journal:
Journal of Crohn's and Colitis
DOI:
10.1093/ecco-jcc/jjy222.088
Date:
January, 2019
File:
PDF, 828 KB
2019
Conversion to is in progress
Conversion to is failed